A synthetic, symmetry-based inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, A77003, was evaluated for antiviral activity and cytotoxicity in vitro in human peripheral blood lymphocytes or cell lines H9, CEM, and U937. Toxicity and antiviral activity of the HIV-1 protease inhibitor were compared with those of the reverse transcriptase inhibitors zidovudine and 2',3'-dideoxy-2',3'-didehydrothymidine and human recombinant alpha and beta interferons. Production of infectious virus particles, cell-free p24 antigen, and cell-associated viral proteins was reduced 50%o by the HIV-1 protease inhibitor at concentrations of 0.12 to 0.26 FM (50%o effective concentration [EC50J) in acute infection and 0.2 to 1.7 ,uM (EC50) in persistent infection. Fluorescence-activated cell sorter analysis of U937 cells persistently infected with HIVmB using a monoclonal antibody to HIV also showed a reduction of cell-associated viral protein in A77003-treated cells.
infection than alpha and beta interferons (1,000 U/ml), while zidovudine and 2',3'-dideoxy-2',3'-didehydrothymidine were not active.
Current treatment for human immunodeficiency virus (HIV) infection is dominated by inhibitors of the viral reverse transcriptase (RT) which act early in the virus life cycle prior to integration (5, 6, 23) . Therapeutic strategies with antiretroviral agents targeting other steps in the life cycle of HIV are of major importance, considering the development of viral resistance against RT inhibitors, ineffectiveness of RT inhibitors in persistently infected cells, and toxicity of these agents (5, 8, 13, 14, 19, 20) . HIV type 1 (HIV-1) has three major genes (gag, pol, and env) which are translated into polyprotein precursors and undergo posttranslational proteolytic cleavage and modification (7) . The gag-pol and gag polyproteins are specifically cleaved by a virally encoded aspartic protease, HIV protease, which is of interest as a target for the development of new antiviral agents (3) . Earlier symmetry-based HIV protease inhibitors developed by Abbott Laboratories, Abbott Park, Ill., were found to inhibit the HIV protease at nanomolar concentrations but had poor water solubility (4, 11) . The terminal residues of lead compounds were substituted to increase water solubility (10) , and the most promising derivative, A77003, was chosen for further evaluation. While previous studies of HIV-1 protease inhibitors and A77003 in particular (10, 11) were based on the antiviral effect against acute HIV infection, we investigated the antiviral effect of A77003 in cultured lymphoid and monocyte cell lines persistently infected with HIVIIIB and HIVMN and in human peripheral blood lymphocytes (PBLs) with established HIVIIIB infection. Our results provide further evidence that A77003 is effective against both acute and persistent infection of dif-ferent cell types with HIV-lMN and HIV-1IIIB at similar concentrations.
MATERIALS AND METHODS
Drugs and compounds. A77003 was provided by Abbott Laboratories. The compound was prepared as a 10 mM stock solution in dimethyl sulfoxide (DMSO). For experiments, the compound was diluted in test media with a maximal final DMSO concentration of 0.1%, which was found to be not toxic to the cells used in this study. HIV focal immunoassay. Titration of infectious HIV produced by acutely and persistently infected cell cultures was performed as described by Chesebro and Wehrly (1) Cell toxicity assay. Cytotoxicity and/or antiproliferative activity of A77003 was assessed by measuring the formation of formazan, a tetrazolium dye, in a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MIT) assay (12) modified as described before (17) . Since DMSO was used to solubilize A77003, control studies were performed to determine a concentration of DMSO (0.1%) which had no effect on cell proliferation in the MTT assay. Day 
RESULTS
Activity and toxicity of A77003 in acutely HIV-1-infected cells. The antiviral activity of A77003 in CEM, H9, and U937 cell lines challenged with HIV-1 strains MN and IIIB was evaluated in parallel to its cytotoxicity. On the basis of reduction of supernatant p24 from acutely infected cells, the EC50s (0.12 to 0.26 ,uM) were similar in all the cell lines and HIV-1 strains tested (Table 1) . A77003 also decreased the titers of supernatant HIV in a concentration-dependent manner (Table 2) . Results obtained with human peripheral lymphocytes treated with A77003 and challenged with HIVIIIB were similar to those obtained with cell lines (Table  1 and 2) .
Additional experiments using FACS analysis and the Western blot (immunoblot) technique were performed to investigate the effect of A77003 on cell-associated HIV-1. Analysis of mean fluorescence intensity (in arbitrary units) 5 days postinfection indicated that continuous exposure to A77003 at a concentration of 1 p,M when started 4 h prior to infection with HIVIIIB resulted in a dose-dependent decrease in cell-associated virus p24 antigen per cell from 107 + 21 to 64 + 31 (mean + SD; the uninfected control had a mean fluorescence intensity of 63 + 24) and a decrease in the total number of HIV-infected cells from 37.4 to 18.5%. Concentrations of A77003 above 1 p,M reduced cell-associated p24 to levels undetectable by both FACS and Western blot analysis. When cultures of U937 cells and PBLs exposed to 1 p,M A77003 for 7 days were washed free of the drug and cultured in drug-free media, virus production was observed by infectivity and p24 assay as early as 36 h after A77003 treatment was discontinued (data not shown).
Toxicity assessed by MTT assay was not observed at the highest concentration of A77003 tested (100 ,uM, continuous exposure for 4 consecutive days) for any of the four cell types. Similarly, cell viability assessed by trypan blue dye exclusion was not significantly reduced when cells were treated for 4 days with 100 ,M A77003. Antiviral activity and toxicity of A77003 in persistently HIV-1-infected cells. The effect of A77003 at different concentrations was compared with those of single concentrations of AZT, d4T, and IFN-a and -,B known to be effective against HIV infection in U937 cells (Fig. 1A ) and in PBLs with established HIVIIIB infection (Fig. 1B) . While RT inhibitors (AZT and d4T) were not active (as expected) in cells with established HIV-1 infection, A77003 inhibited p24 release at concentrations of 0.19 to 1.77 ,uM (Table 1) . In general, A77003 appeared more active in acute infection than in persistent infection. A77003 also reduced the amount of infectious virions in supernatant of persistently HIV-infected cell lines and PBLs with established HIV infection (Table 2) . Western blots of persistently HIVIIIB-infected U937 cells showed a dose-dependent reduction of cellassociated virus gag proteins pr55rag and p24 when cells were treated with A77003 (Fig. 2) . No cell-associated HIV p24 was detected with above 1 ,uM A77003 in Western blot studies, while the RT inhibitors, AZT, d4T, and ddI, did not significantly reduce cell-associated viral gag protein in persistently infected U937 cells.
Importantly, the protease inhibitor was not cytotoxic in MTT assays at a concentration of 100 p,M. In contrast, concentrations of IFN-a and -f (1,000 U/ml), which de- creased virus release from persistently infected cells (Fig. 1)  (17, 18) by 20 to 40%, reduced cell growth and inhibited cellular protein synthesis by 10 to 20% compared with that in the control.
DISCUSSION
The HIV protease is responsible for posttranslational processing of the gag-pol and gag gene products. Inhibition of this processing prevents the release of infectious virus. This process is essential for virus maturation in both acutely and persistently infected cells. Since the crystal structure of the HIV-1 protease alone and in the presence of inhibitors was elucidated (4, 15, 16, 22) , computer-assisted design of these drugs from X-ray diffraction crystallography data allows production of compounds with high specificity. Inhibition of the HIV-1 protease results in a marked suppression of acute virus infection, as was shown recently in other laboratories with A77003 and other C2 symmetric HIV protease inhibitors (9, 10). The results presented in this study confirm those findings, although A77003 was less efficacious in our experimental setting when compared with findings of Kempf et al. (10) , who reported an EC50 for HIV-1MN of 0.03 p,M for acute infection of EM cells. This disparity may be explained by the larger amount of DMSO vehicle used by those colleagues, which could influence antiviral activity, i.e., by altering the permeability of the cells for A77003.
Here we supply evidence that A77003 was an effective inhibitor of infectious virus production in persistently infected cells while, as expected, nucleoside analogs were not. (9) . However, the moderate solubility (197 ,ug/ml at pH 7.4) and low oral bioavailability (<3%) of A77003 known from animal experiments (9, 10) 
